- Home
- AMGN vs ACN Comparison
AMGN vs ACN Comparison
Compare AMGN & ACN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- ACN
- Stock Information
- Founded
- AMGN 1980
- ACN 1989
- Country
- AMGN United States
- ACN Ireland
- Employees
- AMGN N/A
- ACN N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- ACN Business Services
- Sector
- AMGN Health Care
- ACN Consumer Discretionary
- Exchange
- AMGN Nasdaq
- ACN Nasdaq
- Market Cap
- AMGN 150.8B
- ACN 161.9B
- IPO Year
- AMGN N/A
- ACN N/A
- Fundamental
- Price
- AMGN $275.14
- ACN $241.20
- Analyst Decision
- AMGN Hold
- ACN Buy
- Analyst Count
- AMGN 19
- ACN 21
- Target Price
- AMGN $320.11
- ACN $327.33
- AVG Volume (30 Days)
- AMGN 1.9M
- ACN 4.0M
- Earning Date
- AMGN 10-29-2025
- ACN 09-25-2025
- Dividend Yield
- AMGN 3.47%
- ACN 2.45%
- EPS Growth
- AMGN 110.88
- ACN 15.02
- EPS
- AMGN 12.23
- ACN 12.56
- Revenue
- AMGN $34,917,000,000.00
- ACN $68,482,535,999.00
- Revenue This Year
- AMGN $8.94
- ACN $8.05
- Revenue Next Year
- AMGN $1.71
- ACN $5.40
- P/E Ratio
- AMGN $22.45
- ACN $19.21
- Revenue Growth
- AMGN 12.88
- ACN 6.21
- 52 Week Low
- AMGN $253.30
- ACN $235.83
- 52 Week High
- AMGN $339.17
- ACN $398.35
- Technical
- Relative Strength Index (RSI)
- AMGN 37.65
- ACN 36.96
- Support Level
- AMGN $271.61
- ACN $235.83
- Resistance Level
- AMGN $277.80
- ACN $245.20
- Average True Range (ATR)
- AMGN 4.94
- ACN 6.02
- MACD
- AMGN -0.71
- ACN -0.63
- Stochastic Oscillator
- AMGN 20.61
- ACN 21.84
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About ACN Accenture plc (Ireland)
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.